4th Gen EGFR Inhibitor
We are always open to new potential opportunities to establish strategic collaborations.
Genosco’s pipelines consist of 2 assets in Phase II/III, 1 asset in Phase I and multiple preclinical programs.
Genosco is a clinical-stage biotechnology company pursuing the discovery and development of novel small-molecule drugs to treat patients with unmet medical needs.
Partnering with Genosco
We are always open to new potential opportunities to establish strategic collaborations to develop and market our product candidates.